Explore new advancements in lung disease treatment, focusing on idiopathic pulmonary fibrosis and its innovative therapies.

It is a multifactorial therapy that targets several IPF-associated targets concurrently. Qureight will integrate its deep-learning technology into the study, providing imaging core lab services.

Join your peers and key opinion leaders in person and take away critical insights at the only dedicated IPF meeting ... precision medicine to harnessing imaging endpoints in clinical trial ...

a first in IPF patients. Computer tomography (CT) data from the Open Source Imaging Consortium (OSIC) database were analyzed and patient-specific models were generated for two selected cases ...

First-ever use of Ebenbuild's Twinhale technology  in idiopathic pulmonary fibrosis lung modelsTrial results published in Nature Communications Munich, Germany - April 9, 2025 -- Ebenbuild, a company ...